ホーム>>Signaling Pathways>> Immunology/Inflammation>> Specialized Pro-Resolving Mediators>>17(R)-Resolvin D1 methyl ester

17(R)-Resolvin D1 methyl ester (Synonyms: AspirintriggeredResolvin D1 methyl ester, ATRvD1 methyl ester, 17epiResolvin D1 methyl ester, 17(R)RvD1 methyl ester)

カタログ番号GC41227

17(R)-レゾルビンD1(17(R)-RvD1)は、人間の多形核白血球の内皮細胞移行を減少させるアスピリン誘導体であり、急性炎症における最初のイベントです。RvD1と同等の有効性を持ちます(EC50 =〜30 nM)。

Products are for research use only. Not for human use. We do not sell to patients.

17(R)-Resolvin D1 methyl ester 化学構造

Cas No.: 937738-64-2

サイズ 価格 在庫数 個数
10μg
$214.00
在庫あり
25μg
$509.00
在庫あり
50μg
$964.00
在庫あり
100μg
$1,692.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

17(R)-Resolvin D1 (17(R)-RvD1) is an aspirin-triggered epimer of RvD1 that reduces human polymorphonuclear leukocyte transendothelial migration, the earliest event in acute inflammation, with equipotency to RvD1 (EC50 = ~30 nM). 17(R)-RvD1 exhibits a dose-dependent reduction in leukocyte infiltration in a mouse model of peritonitis with maximal inhibition of ~35% at a 100 ng dose. In contrast to RvD1, the aspirin-triggered form resists rapid inactivation by eicosanoid oxidoreductases. 17(R)-RvD1 methyl ester is a methyl ester version of the free acid which may act as a lipophilic prodrug form that will alter its distribution and pharmacokinetic properties. The methyl ester moiety is susceptible to cleavage by intracellular esterases, leaving the free acid.

レビュー

Review for 17(R)-Resolvin D1 methyl ester

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 17(R)-Resolvin D1 methyl ester

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.